Nabriva Therapeutics (NASDAQ:NBRV) Earns Hold Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV) in a research report issued to clients and investors on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.

Nabriva Therapeutics Price Performance

Nabriva Therapeutics has a 1-year low of $1.22 and a 1-year high of $8.45. The stock has a market capitalization of $45.46 million, a PE ratio of -0.07 and a beta of 1.53. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.52 and a current ratio of 0.85.

Nabriva Therapeutics Company Profile

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.